Wenxin Xu MD

Genitourinary Oncology

Genitourinary Oncologist and Instructor in Medicine, Dana-Farber Cancer Institute

450 Brookline AveBoston, MA 02215
Phone+1 617-632-3466
Fax+1 617-632-2165

Dr. Xu is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Xu's full profile Already have an account?

Summary

Dr. Wenxin Xu is an oncologist specializing in genitourinary oncology, currently practicing at Dana-Farber Cancer Institute in Boston, MA. He completed his medical education at Harvard Medical School and pursued a residency and fellowship at Beth Israel Deaconess Medical Center in internal medicine and hematology/medical oncology, respectively. Dr. Xu leads research focused on the discovery and validation of biomarkers for kidney cancer, and development of new immunotherapies for this disease.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
Harvard Medical SchoolClass of 2014

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NH State Medical License 2022 - 2028
MA State Medical License 2018 - 2027
ME State Medical License 2022 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Young Investigator Award Conquer Cancer Foundation, 2020

Publications & Presentations

PubMed

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC.
Wenxin Xu, Joseph V Bonventre, Toni K Choueiri
Nature Reviews. Clinical Oncology. 2026-08-01
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
Sara Coca Membribes, Wenxin Xu, Cristina Suárez, Poulam M Patel, James Larkin
European Urology. 2026-08-01
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.
Wenxin Xu, Brian I Rini, Laurence Albiges, Xiaobin Tang, Hartmut Koeppen
European Urology. 2026-04-25

Press Mentions

Breast, Lung, and Bladder Cancer Phase 3 Trials Led by Dana-Farber Presented at ESMO Congress 2025October 13th, 2025
Dana-Farber Leads Phase 3 Trials for Breast, Lung, and Bladder Cancer Unveiled at ESMO Congress 2025October 13th, 2025
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers SymposiumFebruary 11th, 2025